Developing drugs to improve immune response in the brain for treating multiple sclerosis
Development of Drugs that Modify CNS Innate Immunity for the Treatment of Multiple Sclerosis
This study is looking at how certain brain cells affect multiple sclerosis and is testing a new drug, A-38, that might help reduce inflammation and damage in the brain, with hopes of finding better treatments for progressive MS and other brain conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10606625 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain cells in the brain, like astrocytes and microglia, contribute to the progression of multiple sclerosis (MS). The team has created a laboratory test to find new drugs that can modify the harmful activities of these brain cells. One promising compound, A-38, has been identified as a potential treatment by inhibiting a specific receptor that influences inflammation and neurodegeneration in the central nervous system. The goal is to develop new versions of this compound to effectively treat progressive MS and possibly other neurological disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with progressive multiple sclerosis.
Not a fit: Patients with non-progressive forms of multiple sclerosis or other unrelated neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or halt the progression of multiple sclerosis.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in the central nervous system, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Quintana, Francisco J. — Brigham and Women's Hospital
- Study coordinator: Quintana, Francisco J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.